CARE OPTIONS

Yes. When clinically appropriate, our clinicians may prescribe hormone therapy based on symptoms, medical history, and current medical guidelines. Decisions are individualized and made carefully—not everyone needs or is a candidate for hormone therapy.

What research suggests:
Hormone therapy is the most effective treatment for vasomotor symptoms when used appropriately and in suitable candidates, according to major medical organizations.

 We focus on FDA-approved medications with established safety, dosing consistency, and evidence of effectiveness. Our clinicians prioritize treatments supported by clinical research and professional guidelines. 

 We focus on FDA-approved options and do not routinely prescribe compounded hormone products, pellets, or injections. Our approach emphasizes safety, consistency, and evidence-based care—especially for long-term use. 

 At this time, we do not prescribe testosterone. The use of testosterone in women is an evolving area of research, and current US guidelines recommend a cautious, limited approach. We continuously monitor the evidence and update our care models as guidance evolves. 

Yes. When hormonal therapy is not recommended or not preferred, Sybil Health clinicians do prescribe FDA-approved non-hormonal medications to help manage certain menopausal symptoms, particularly hot flashes and night sweats.

Depending on individual symptoms and medical history, this may include specific SSRIs or SNRIs that have evidence for reducing vasomotor symptoms, as well as newer non-hormonal options such as fezolinetant (brand name Veozah), an FDA-approved neurokinin-3 (NK3) receptor antagonist.

What research suggests:
Clinical guidelines support the use of both selected antidepressants (SSRIs/SNRIs) and newer non-hormonal therapies for vasomotor symptoms when hormone therapy is not appropriate. Fezolinetant represents a newer class of treatment that targets thermoregulation pathways without using hormones, expanding evidence-based options for symptom relief.

References (APA):
The North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. https://pubmed.ncbi.nlm.nih.gov/37252752/
U.S. Food and Drug Administration. (2023). FDA approves novel drug to treat moderate to severe hot flashes caused by menopause. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
U.S. Food and Drug Administration. (2023). VEOZAH (fezolinetant) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf

Decisions are based on symptom patterns, medical and family history, personal preferences, labs (if available) and current clinical guidelines. Care is individualized—there is no single pathway that fits everyone. 

 Yes. Our clinical approach aligns with guidance from leading professional organizations, including the North American Menopause Society (NAMS) and the American College of Obstetricians and Gynecologists (ACOG).

• NAMS: https://www.menopause.org
• ACOG: https://www.acog.org/womens-health
   

Our clinicians stay current as recommendations evolve.

Many services focus primarily on rapid prescribing.
Sybil Health focuses on clinical context and pattern recognition—looking at how symptoms evolve over time and using evidence-based frameworks to guide decisions.

Care is designed to be thoughtful, cautious, and adaptable—not rushed.

Care begins with a structured intake that captures symptom history, timing, and context. A licensed clinician (MD) reviews this information and provides personalized guidance and next steps.

This may include prescriptions, recommendations, or monitoring, depending on what’s appropriate.

Not always. Hormone levels fluctuate significantly during perimenopause, and labs alone do not always reflect symptom experience. In many cases, clinical context is as important as laboratory values.

 Consultation pricing is transparent and shown upfront. Medication costs, if prescribed, are separate and depend on pharmacy and insurance coverage. 

 Yes. We accept HSA and FSA payments for consultations. 

Currently, consultations are self-pay. We are actively working toward accepting private medical insurance, with plans to support insurance billing in the coming months.